Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @FierceBiotech
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @FierceBiotech
-
Glenmark officially unveiled Ichnos in October. Its headquarters, as well as a development site, are in Paramus, New Jersey, but it maintains R&D sites overseashttps://www.fiercebiotech.com/biotech/novartis-oncology-veterans-reunite-at-glenmark-spinoff-ichnos …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Some of that cash will be used to help boost the launch of Palforzia, but it’s immediately eyeing the future, spending a mere $10 million upfront, with $385 million in biobucks wedded to it, to license Xencor’s XmAb7195.https://www.fiercebiotech.com/biotech/armed-nestle-cash-aimmune-grabs-experimental-food-allergy-drug-form-xencor …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Regeneron has previously applied its antibody discovery capabilities to pathogens including Ebola and Middle East respiratory syndrome coronavirus (MERS-CoV).https://www.fiercebiotech.com/biotech/after-ebola-success-regeneron-turns-antibody-capabilities-against-2019-ncov …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This comes as thre Big Pharma is splitting into two companies:https://www.fiercebiotech.com/biotech/gsk-culls-oncology-hopeful-officially-tosses-out-failed-hiv-vax …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lyon, France-based MaaT is one of a clutch of drug developers trying to treat disease by restoring the microbiome.https://www.fiercebiotech.com/biotech/maat-bags-eu18m-to-test-microbiome-modulators-cancer-patients …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Passage ended 2019 with $158.9 million in the bank and now expects its phase 1/2 gangliosidosis trial to kick off in the second half of 2020, with trials for the dementia and Krabbe candidates to follow in the first half of 2021https://www.fiercebiotech.com/biotech/after-bagging-200m-2019-passage-bio-guns-for-125m-ipo …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bio Fund III dwarfs its two predecessors, which totaled $650 million together. And that’s not all—a16z has built a team around its biotech and healthcare efforts.https://www.fiercebiotech.com/biotech/a16z-unveils-750m-fund-to-bankroll-startups-at-intersection-tech-medicine …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Vanda publicly framed its lawsuit against the FDA as a stand against “unnecessary animal research.”https://www.fiercebiotech.com/biotech/fda-wins-legal-dispute-vanda-over-partial-clinical-hold …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
She comes to the company half a year after Humphrey, who had headed up immuno-oncology at AstraZeneca and Eli Lilly, made her exit.https://www.fiercebiotech.com/biotech/after-losing-its-cmo-last-summer-cytomx-therapeutics-finally-nabs-a-replacement …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioMotiv, an accelerator linked to the $340 million Harrington Project for Discovery & Development, teamed up with Bristol-Myers in September.https://www.fiercebiotech.com/biotech/bristol-myers-forms-fibrotic-disease-biotech-bags-buyout-option …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bio Fund III dwarfs its two predecessors, which totaled $650 million together. And that’s not all—a16z has built a team around its biotech and healthcare efforts.https://www.fiercebiotech.com/biotech/a16z-unveils-750m-fund-to-bankroll-startups-at-intersection-tech-medicine …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Insmed licensed INS1007 from AstraZeneca in October 2016 for $30 million upfront and $120 million in milestones down the line.https://www.fiercebiotech.com/biotech/insmed-s-inflammatory-lung-disease-drug-makes-grade-phase-2 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Gilead publicly floated the idea of using remdesivir to treat the coronavirus, dubbed 2019-nCoV, 10 days ago. Since then, the effort to advance the drug in the indication has gathered pace.https://www.fiercebiotech.com/biotech/gilead-climbs-as-coronavirus-drug-shows-efficacy-starts-trial …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Craig Basson joins the early-stage private biotech after serving at the Swiss Big Pharma for a decadehttps://www.fiercebiotech.com/biotech/boston-pharmaceuticals-nabs-novartis-veteran-as-new-cmo …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CEPI is supporting programs to develop coronavirus vaccines underway at groups including Inovio Pharmaceuticals and Moderna. The agreement with GSK positions CEPI to expand the support it can offer partner organizationshttps://www.fiercebiotech.com/biotech/gsk-makes-adjuvant-available-to-coronavirus-vaccine-project …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
VX-961 fell at the first hurdle. On Vertex’s fourth-quarter results conference call with investors, Reshma Kewalramani, the company’s chief medical officer, said the phase 1 showed VX-961 lacked the desired pharmacokinetic and tolerability profile.https://www.fiercebiotech.com/biotech/vertex-drops-vx-961-to-continue-search-for-perfect-pain-drug …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Chutes & Ladders—Ex-Takeda exec Ivarsson joins Moderna as CDOhttps://www.fiercebiotech.com/biotech/chutes-ladders-ex-takeda-exec-ivarsson-joins-moderna-as-cdo …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The bad news? These percentages drop for both women and people of color as you look up the ranks. Women make up 30% of executive teams and 18% of biotech company board members, while those numbers are 15% and 14% for people of color, respectively.https://www.fiercebiotech.com/biotech/we-can-do-better-bio-s-first-breakdown-diversity-member-companies …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At the bottom of page 17 of its financial presentation, released as part of its full-year/Q4 results, are three experimental drugs stuck at the bottom of table with a big red arrow pointing down: Translation, they’ve been cut.https://www.fiercebiotech.com/biotech/eli-lilly-cuts-three-cancer-drugs-amid-q4-clear-out …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ivarsson joins Moderna as it drives its hefty pipeline forward. One would think that with 21 programs, Moderna has its hands full. But it looks like the mRNA biotech is planning to build out its pipeline even more.https://www.fiercebiotech.com/biotech/ex-shire-takeda-clinical-trials-chief-melanie-ivarsson-lands-at-moderna …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.